Mitoxantrone, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine are toll-like receptor 4 antagonists, inhibit...

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Toll-like receptor 4 (TLR4) is a key component of the innate immune system, recognizing various ligands and initiating inflammatory responses via NF-κB signaling.
• Dysregulated TLR4 signaling is implicated in numerous diseases, including stroke, neuropathic pain, multiple sclerosis, rheumatoid arthritis, and cancer, highlighting the need for novel therapeutics.
• Current therapeutic strategies targeting TLR4 are limited, necessitating the exploration of new inhibitory compounds.

Purpose of the Study:

• To identify novel inhibitors of Toll-like receptor 4 (TLR4) and its associated NF-κB signaling pathway.
• To investigate the mechanism of action of identified compounds, particularly their direct interaction with TLR4 and their effect on cytokine production.
• To evaluate the potential therapeutic applications of these inhibitors in the context of TLR4-mediated inflammatory conditions.

Main Methods:

• Virtual screening of a large compound library (140,000 compounds) followed by experimental validation using a cellular reporter system.
• Biochemical assays to confirm direct binding of compounds to TLR4.
• Measurement of proinflammatory cytokine production (e.g., TNFα) in primary microglia.
• Cytotoxicity assessment using ATP counts to ensure non-toxic concentrations of inhibitors.

Main Results:

• Mitoxantrone and its analogues, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine, were identified as potent inhibitors of TLR4 and NF-κB activation.
• Mitoxantrone demonstrated direct binding to TLR4.
• Pixantrone and mitoxantrone (2-hydroxyethyl)piperazine effectively inhibited the production of tumor necrosis factor alpha (TNFα) in primary microglia without significant cytotoxicity at ≤ 1 µM.
• The observed inhibition of NF-κB activation and TNFα production was not due to cytotoxicity.

Conclusions:

• Mitoxantrone, pixantrone, and mitoxantrone (2-hydroxyethyl)piperazine represent a new class of TLR4 inhibitors.
• These compounds exert their inhibitory effects through a novel mechanism involving direct interaction with TLR4.
• The findings suggest a potential therapeutic role for these compounds in treating diseases associated with aberrant TLR4 activation and inflammation.